T
Thomas A. Abrams
Researcher at Harvard University
Publications - 98
Citations - 6237
Thomas A. Abrams is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 29, co-authored 85 publications receiving 5497 citations. Previous affiliations of Thomas A. Abrams include University of California, Los Angeles & Dana Corporation.
Papers
More filters
Journal ArticleDOI
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
Al B. Benson,Thomas A. Abrams,Edgar Ben-Josef,P. Mark Bloomston,Jean F. Botha,Bryan M. Clary,Anne M. Covey,Steven A. Curley,Michael I. D'Angelica,Rene Davila,William D. Ensminger,John F. Gibbs,Daniel Laheru,Mokenge P. Malafa,Jorge Marrero,Steven G. Meranze,Sean J. Mulvihill,James O. Park,James A. Posey,Jasgit Sachdev,Riad Salem,Elin R. Sigurdson,Constantinos T. Sofocleous,Jean-Nicolas Vauthey,Alan P. Venook,Laura W. Goff,Yun Yen,Andrew X. Zhu +27 more
Journal ArticleDOI
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu,Dushyant V. Sahani,Dan G. Duda,Emmanuelle di Tomaso,Marek Ancukiewicz,Onofrio A. Catalano,Vivek Sindhwani,Lawrence S. Blaszkowsky,Sam S. Yoon,Johanna Lahdenranta,Pankaj Bhargava,Jeffrey A. Meyerhardt,Jeffrey W. Clark,Eunice L. Kwak,Aram F. Hezel,Rebecca A. Miksad,Thomas A. Abrams,Peter C. Enzinger,Charles S. Fuchs,David P. Ryan,Rakesh K. Jain +20 more
TL;DR: Sunitinib shows evidence of modest antitumor activity in advanced HCC with manageable adverse effects and Rapid changes in tumor vascular permeability and circulating inflammatory biomarkers are potential determinants of response and resistance to sunitinIB in HCC.
Journal ArticleDOI
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin,Aram F. Hezel,Thomas A. Abrams,Lawrence S. Blaszkowsky,Jeffrey A. Meyerhardt,Jennifer A. Chan,Peter C. Enzinger,Brittany Allen,Jeffrey W. Clark,David P. Ryan,Charles S. Fuchs +10 more
TL;DR: Although well-tolerated, RAD001 administered as a single-agent had minimal clinical activity in patients with gemcitabine-refractory, metastatic pancreatic cancer, suggesting the combination of mTOR inhibitors with other agents and/or examine inhibitors of other components of the PI3K/Akt/mTOR pathway.
Journal ArticleDOI
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
Andrew X. Zhu,Jeffrey A. Meyerhardt,Lawrence S. Blaszkowsky,Avinash Kambadakone,Alona Muzikansky,Hui Zheng,Jeffrey W. Clark,Thomas A. Abrams,Jennifer A. Chan,Peter C. Enzinger,Pankaj Bhargava,Eunice L. Kwak,Jill N. Allen,Sanjay Jain,Keith Stuart,Kerry Horgan,Susan Sheehan,Charles S. Fuchs,David P. Ryan,Dushyant V. Sahani +19 more
TL;DR: GEMOX-B showed antitumour activity with tolerable safety in patients with advanced BTCs, and decreases in SUV(max) on 18-fluorodeoxyglucose-PET scans after treatment were associated with disease control and increases in PFS and overall survival.
Journal ArticleDOI
Hepatobiliary Cancers, Version 1.2017: Featured Updates to the NCCN Guidelines
Al B. Benson,Michael I. D’Angelica,Daniel E. Abbott,Thomas A. Abrams,Steven R. Alberts,Daniel Anaya Saenz,Chandrakanth Are,Daniel B. Brown,Daniel T. Chang,Anne M. Covey,William G. Hawkins,Renuka Iyer,Rojymon Jacob,Andrea Karachristos,R. Kate Kelley,Robin D. Kim,Manisha Palta,James O. Park,Vaibhav Sahai,Tracey E. Schefter,Carl Schmidt,Jason K. Sicklick,Gagandeep Singh,Davendra Sohal,Stacey Stein,G. Gary Tian,Jean Nicolas Vauthey,Alan P. Venook,Andrew X. Zhu,Karin G. Hoffmann,Susan Darlow +30 more
TL;DR: The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.